Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-057 in moderately to severely active ulcerative colitis
NCT05291689Phase 2Completed
- Sponsor
- Morphic Therapeutic
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LY4268989 in ulcerative colitis (UC), sponsored by Morphic Therapeutic. Started Apr 2022; status: completed.
02
Drugs
LY4268989
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05291689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291689.